Advanced search
Publication Cover
Journal of Medical Economics Volume 26, 2023 - Issue 1
Submit an article Journal homepage
872
Views
0
CrossRef citations to date
0
Altmetric
Genetic Disease

Re: Response letter to Sanofi’s communication related to “the budget impact of enzyme replacement therapy in type 1 Gaucher disease in the United States”

Sepehr Farahbakhshiana US Medical, Takeda Pharmaceuticals U.S.A., Inc., Lexington, MA, USACorrespondence[email protected]
,
Timothy J. Inocenciob Modeling and Meta-analysis, OPEN Health, Bethesda, MD, USA
,
Gregory Poormanb Modeling and Meta-analysis, OPEN Health, Bethesda, MD, USA
,
Ekaterina Wrighta US Medical, Takeda Pharmaceuticals U.S.A., Inc., Lexington, MA, USA
,
Ravi Ramesh Pathaka US Medical, Takeda Pharmaceuticals U.S.A., Inc., Lexington, MA, USA
&
Michael Bullanoa US Medical, Takeda Pharmaceuticals U.S.A., Inc., Lexington, MA, USAORCID Iconhttps://orcid.org/0000-0002-9961-4576
ORCID Icon
Pages 581-583 | Received 28 Mar 2023, Accepted 29 Mar 2023, Published online: 17 Apr 2023

References

  • Farahbakhshian S, Inocencio TJ, Poorman G, et al. The budget impact of enzyme replacement therapy in type 1 gaucher disease in the United States. J Med Econ. 2022; 25(1):755–761.
  • Revel-Vilk S, Szer J, Mehta A, et al. How we manage Gaucher disease in the era of choices. Br J Haematol. 2018;182(4):467–480.
  • Van Rossum A, Holsopple M. Enzyme replacement or substrate reduction? A review of gaucher disease treatment options. Hosp Pharm. 2016;51(7):553–563.
  • CERDELGA™ (eliglustat) ([package insert]), Genzyme Corporation, a Sanofi Company, Waterford, Ireland, August 2014; [cited 2023 Jan 26]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/205494s003lbl.pdf.
  • Guggenbuhl P, Grosbois B, Chales G. Gaucher disease. Joint Bone Spine. 2008;75(2):116–124.
  • Peterschmitt JM, Cox GF, Ibrahim J, et al. A pooled analysis of adverse events in 393 adults with Gaucher disease type 1 from four clinical trials of oral eliglustat: evaluation of frequency, timing, and duration. Blood Cells Mol Dis. 2018;68:192–193.
  • Mistry PK, Lukina E, Ben Turkia H, et al. Effect of oral eliglustat on splenomegaly in patients with gaucher disease type 1: the ENGAGE randomized clinical trial. JAMA. 2015;313(7):695–706.
  • Pharmaceutical Benefits Advisory Committee. 2015. Public Summary Document. ELIGLUSTAT, oral capsule, 100 mg, Cerdelga®, Genzyme.
  • Canadian Agency for Drugs and Technologies in Health 2017. CADTH Common Drug Review. Clinical Review Report for Eliglustat (Cerdelga).
  • Burrow TA, Grabowski GA. Velaglucerase alfa in the treatment of Gaucher disease type 1. Clin Investig. 2011;1(2):285–293.
  • Brumshtein B, Salinas P, Peterson B, et al. Characterization of gene-activated human acid-beta-glucosidase: crystal structure, glycan composition, and internalization into macrophages. Glycobiology. 2010;20(1):24–32.
  • Dinur T, Grittner U, Revel-Vilk S, et al. Impact of long-term enzyme replacement therapy on glucosylsphingosine (Lyso-Gb1) values in patients with type 1 gaucher disease: statistical models for comparing three enzymatic formulations. Int J Mol Sci. 2021;22(14):7699.
  • VPRIV™ (velaglucerase alfa) ([package insert]); [cited 2020 Jan 24]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022575s026lbl.pdf.
  • Lau H, Belmatoug N, Deegan P, et al. Reported outcomes of 453 pregnancies in patients with Gaucher disease: an analysis from the Gaucher outcome survey. Blood Cells Mol Dis. 2018;68:226–231.
  • Smith L, Rhead W, Charrow J, et al. Long-term velaglucerase alfa treatment in children with Gaucher disease type 1 naïve to enzyme replacement therapy or previously treated with imiglucerase. Mol Genet Metab. 2016; 117 (2):164–171.
  • Hughes DA, Gonzalez DE, Lukina EA, et al. Velaglucerase alfa (VPRIV) enzyme replacement therapy in patients with Gaucher disease: long-term data from phase III clinical trials. Am J Hematol. 2015;90(7):584–591.
  • Balwani M, Burrow TA, Charrow J, et al. Recommendations for the use of eliglustat in the treatment of adults with Gaucher disease type 1 in the United States. Mol Genet Metab. 2016;117(2):95–103.
  • Elstein D, Hughes D, Goker-Alpan O, et al. Outcome of pregnancies in women receiving velaglucerase alfa for Gaucher disease. J Obstet Gynaecol Res. 2014;40(4):968–975.
  • Granovsky-Grisaru S, Belmatoug N, Vom Dahl S, et al. The management of pregnancy in Gaucher disease. Eur J Obstet Gynecol Reprod Biol. 2011;156(1):3–8.
  • Sekijima Y, Ohashi T, Ohira S, et al. Successful pregnancy and lactation outcome in a patient with Gaucher disease receiving enzyme replacement therapy, and the subsequent distribution and excretion of imiglucerase in human breast milk. Clin Ther. 2010;32(12):2048–2052.
  • ZAVESCA® (miglustat), ([package insert]), Actelion; [cited 2020 Jan 26]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021348s016lbl.pdf.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.